Lirimilast (BAY 19-8004) is a potent, selective and orally active phosphodiesterase-4 (PDE4) inhibitor with an IC50 value of 49 nM. Lirimilast can be used for the treatment of asthma or chronic obstructive pulmonary disease (COPD). Lirimilast has potently anti-inflammatory properties[1][2].
Molecular Weight:
443.26
Purity:
98.69
CAS Number:
[329306-27-6]
Formula:
C17H12Cl2N2O6S
Target:
Phosphodiesterase (PDE)
Application Notes:
Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted